We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+33.34%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$511M
AUM Growth
+$93.5M
Cap. Flow
+$56.7M
Cap. Flow %
11.08%
Top 10 Hldgs %
80.15%
Holding
29
New
13
Increased
1
Reduced
1
Closed
7

Top Buys

Rank Stock Value
1
LONA
LeonaBio Inc
LONA
+$25.4M
2
IMV
IMV Inc. Common Shares
IMV
+$18M
3
ALXO icon
ALX Oncology
ALXO
+$11.8M
4
MTCR
Metacrine, Inc. Common Stock
MTCR
+$11.7M
5
COGT icon
Cogent Biosciences
COGT
+$11.4M

Top Sells

Rank Stock Value
1
VXRT
Vaxart
VXRT
+$24.5M
2
MYOV
Myovant Sciences Ltd.
MYOV
+$17.4M
3
NARI
Inari Medical, Inc. Common Stock
NARI
+$11.4M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$8.55M
5
ADAP
Adaptimmune Therapeutics
ADAP
+$7.83M

Sector Composition

Rank Sector Weight
1 Healthcare 72.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NARI
26
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-235,000
Closed -$11.4M
MYOV
27
DELISTED
Myovant Sciences Ltd.
MYOV
– –
-845,000
Closed -$17.4M
SRRA
28
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-378,888
Closed -$4.58M
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q3 2020 Portfolio in Review

As of Q3 2020, VR Adviser held 29 positions worth $511M, up 22% from $418M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

VR Adviser deployed $56.7M of net new capital in Q3 2020, opening 13 new positions and adding to 1 existing holding. Its largest new stake was LeonaBio Inc: 152,162 shares worth $28.1M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 83% a quarter earlier.

On the sell side, the largest reduction was Marinus Pharmaceuticals, Inc, an estimated $2.06M trimmed.

  • VR Adviser's largest Q3 2020 buy was LeonaBio Inc: 152,162 shares worth $28.1M.
  • VR Adviser added most to Trillium Therapeutics Inc. in Q3 2020, an estimated $4.13M increase.
  • VR Adviser's biggest Q3 2020 reduction was Marinus Pharmaceuticals, Inc, cutting an estimated $2.06M.
  • VR Adviser fully exited Vaxart in Q3 2020, selling an estimated $24.5M.
  • VR Adviser's ten largest holdings make up 80% of its $511M portfolio in Q3 2020.
  • VR Adviser opened 13 new positions and closed 7 in Q3 2020.
  • VR Adviser's portfolio value rose 22% quarter-over-quarter to $511M.

Based on VR Adviser's 13F filing for Q3 2020, filed 16 Nov 2020.